Some of our Favourites from 2021 – Happy New Year!

Dear Subscriber,

We are nearing the end of 2021 and we look forward to bringing you more of the very best from the medical literature on anti-NMDA receptor encephalitis and autoimmune encephalitis in 2022. We hope you have found our weekly selections of value.

Before closing the year, we thought we would share with you some of our favourites and ones we consider important articles from 2021. This was a daunting task as there has been so much valuable literature. We are pleased to share with you our picks of eleven articles from 2021, chosen from our newsletters.

Thank you for supporting our efforts. And, of course, if you wish to make a year-end contribution, (Canadians will receive a tax-deductible receipt) you still have time until midnight, 31 December 2021.



Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis

Screening for pathogenic neuronal autoantibodies in serum and CSF of patients with first-episode psychosis

Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis

Rituximab Treatment and Long-term Outcome of Patients with Autoimmune Encephalitis

CSF Findings in Acute NMDAR and LGI1 Antibody–Associated Autoimmune Encephalitis

Neural Antibody Testing for Autoimmune Encephalitis: A Canadian Single-Centre Experience

Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis

Long-Term Cognitive Outcome in Anti–N-Methyl-D-Aspartate Receptor Encephalitis

Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis

Autoimmune Neurology
The Need for Comprehensive Care

ExTINGUISH Trial Announcement